Two multiplex PCR screening capabilities (TaqMan Array Cards and FilmArray) were evaluated for their ability to detect Bacillus anthracis, Francisella tularensis and Yersinia pestis in blood samples obtained from respective murine infection models. Blood samples were obtained from infected mice at 24 h intervals after exposure. Multiplex PCR results were compared with standard blood culture and singleplex real-time PCR. Across all three models, 71 mice were tested in total, within which a subset of 43 samples was shown to contain an infecting agent by at least one of the detection technologies. Within this subset of positive samples, for each model studied, the detection rates of each technology were compared. The B. anthracis model blood culture (14 of 15 agent-containing samples tested) and FilmArray PCR (12 of 15) were shown to have equivalent detection rates, which were significantly higher (at the 95 % confidence level) than singleplex (five of 14) or Array Card (two of 14) PCRs. The F. tularensis model blood culture (12 of 12) was shown to have a significantly higher (at 95 % confidence level) detection rate than all PCR technologies, with FilmArray (seven of 11) and singleplex (seven of 12) PCRs shown to have significantly higher (at 95 % confidence level) detection rates than the Array Card PCR (two of 11). Within the Y. pestis model, there was no significant difference in detection rates between blood culture (10 of 16), singleplex PCR (14 of 16), Array Card PCR (10 of 16) and FilmArray PCR (10 of 13).
INTRODUCTION
PCR is commonly used to detect many bacterial pathogens from different sample types (Mitchell et al., 2010; Rose et al., 2011; Weller et al., 2000) . A PCR assay asks a biased question of a sample, i.e. 'do you contain agent X?' To act as a screening capability, where one sample is analysed by a panel of PCR assays for multiple agents, PCRs must be multiplexed, where multiple reactions are carried out in a single tube (Janse et al., 2010) , or an engineering solution such as microfluidics (Kodani et al., 2011; Rachwal et al., 2012) or robotics (Hondow et al., 2011 ) must be found. When considering the advantages offered by PCR technology (sensitivity and specificity), approaches that mitigate the primary disadvantage (a biased assay) will help to unlock the full potential of PCR for diagnostic purposes. The ability of conventional single-tube (singleplex) realtime PCR systems to act as a screening capability is limited by factors such as the number of available reaction chambers, the operative burden and the amount of DNA extract available to analyse.
Early diagnosis of the causative agent of acute infections is important, as rapid identification of the causative agent will lead to deployment of the most appropriate therapy, thereby improving the chance of patient survival (Kumar et al., 2006) . However, many diseases have similar initial 'flu-like' symptoms, which can hinder diagnosis and also make it difficult to select which diagnostic tests for specific infectious agents to conduct.
In this paper, we evaluated two real-time PCR-based screening capabilities, with the potential to aid diagnosis of a number of different diseases, against blood samples generated from three murine models. Each model had an aetiological bacterial agent able to cause acute disease: Bacillus anthracis (anthrax), Francisella tularensis (tularaemia) and Yersinia pestis (plague). One screening capability (TaqMan Array Cards) comprised a prototype system based on a microfluidic card architecture commonly used for gene-expression studies. The initial development and evaluation of this screening capability have been described previously (Rachwal et al., 2012) and it contained PCR assays that have been developed from our own research programmes. The other capability (FilmArray) was a commercial off-the shelf product based on a microfluidic pouch system containing modules for DNA extraction and purification and an array of PCRs deigned, developed and evaluated by the manufacturer (Idaho Technologies).
METHODS
Murine models. Mouse models of infection, from an extant project used to establish the performance of singleplex PCR, were used to evaluate the performance of the multiplex PCR capabilities in clinical sample types. The B. anthracis model used the Russian vaccine strain (STI), which does not harbour the pXO2 virulence plasmid. AJ strain female mice (Harlan Laboratories) were inoculated via an intraperitoneal route at a dosage of 1.7610 6 c.f.u. per mouse. The Y. pestis model used the CO92 strain. Female BALB/c mice, aged 6-8 weeks, were inoculated via a subcutaneous infection route at a dosage of 7610 2 c.f.u. per mouse. The F. tularensis model used the Schu 4 strain. Female BALB/c mice, aged 6-8 weeks, were inoculated via an inhalational route. Ten millilitres of culture was aerosolized using a Henderson apparatus over an exposure time of 10 min, as described previously (Eyles et al., 2008) . The aerosol was delivered at a flow rate of 12 l min 21 with impinger samples from the exposure apparatus plated on blood-cysteine-glucose agar to calculate a retained dose of 24 c.f.u. per mouse. Low-dose challenges were chosen for each agent so that the animals developed an infection over the 4-day period of the study, but also so they did not quickly succumb to infection. As each agent was different, and had a different lethal dose (LD 50 ), the challenge doses varied among the agents.
Blood samples were harvested from mice at time points of 24, 48 and 72 h post-infection (p.i.). Humane end points were strictly observed; for example, in the anthrax model, mice assigned a 96 h time point were culled after 72 h due to clinical signs indicating that they had a lethal infection. Blood from each mouse was collected into BD Vacutainer collection tubes (Becton Dickinson) containing 0.105 M buffered sodium citrate solution. All research was conducted in strict accordance with the Animals (Scientific Procedures) Act 1986.
Bacterial culture. The presence of viable bacteria in blood samples was determined by plating two 100 ml aliquots of each blood sample onto an appropriate medium. Cultures were incubated at 37 uC. Bacterial loads were estimated by serially diluting each blood sample in 16 Dulbecco's PBS (Life Technologies), followed by cultivation of three 100 ml aliquots of each dilution. Samples from the B. anthracis model were incubated on nutrient agar, F. tularensis model samples on blood-cysteine-glucose agar and Y. pestis model samples on blood agar base. All media were produced in house using commonly available recipes. Counts were performed from the most appropriate dilution according to bacterial load.
Singleplex and Array Card real-time PCR. As part of the extant project, DNA was extracted from collected blood samples using a DNeasy Blood and Tissue kit (Qiagen) from 100 ml starting volumes. The resulting DNA extracts were then tested by PCR under Biological Safety Level 3 (BSL3) containment or sterility checked to enable samples to be analysed under BSL2 containment.
Seven real-time PCR assays were used in this study. The development and validation of the F. tularensis PCRs have been described previously (Mitchell et al., 2010) , and the performance of all seven PCRs in singleplex and Array Card format has also been reported (Rachwal et al., 2012) . All B. anthracis and Y. pestis PCR assays have been shown to be specific for their target genes/agents with the exception of the Y. pestis mpbA assay, which has been shown also to detect Yersinia pseudotuberculosis. For the B. anthracis PCRs, these studies included DNA from 25 B. anthracis and 28 other Bacillus spp., and for the Y. pestis PCRs, DNA from seven Y. pestis strains and 25 other Yersinia spp. was included (data not shown).
In singleplex format, PCR assays were used with optimized PCR primer concentrations (Table S1 , available in JMM Online). PCR probes were covalently labelled at the 59 end with the fluorescent reporter dye 6-carboxyfluorescein (6-FAM) and a minor groove binder (MGB) or Black Hole Quencher 1 (BHQ1) dye at the 39 end. Real-time PCRs (25 ml reaction volume) comprised forward and reverse primers, probe (0.2 mM), 16 PCR master mix [containing 50 mM Tris/HCl (pH 8.8), 50 mM EGTA, 1 mg BSA ml 21 , 4 mM MgCl 2 , 0.04 U JumpStart Taq polymerase ml 21 (Sigma-Aldrich) and 200 mM dNTPs], sterile water and template DNA or sample extract (10 ml). Singleplex PCRs were performed on the SmartCycler PCR platform (Cepheid) using a thermocycling profile consisting of 95 uC for 3 min, followed by 50 cycles of 95 uC for 15 s and 60 uC for 30 s. Within each PCR run, two reaction tubes were loaded with water instead of DNA extract to serve as a negative control. Real-time PCR results were reported in terms of quantitative cycle threshold value (C q ), the cycle number within which fluorescence first exceeded 30 U in each PCR.
The DNA extracts produced as part of the extant project were used to assay the performance of the TaqMan Array Card (Life Technologies) described previously (Rachwal et al., 2012) . The Array Cards were produced so that the same PCR assays used in the extant singleplex PCR project were also present on the cards. Probes were labelled at their 59 end with 6-FAM and at the 39 end with MGB or N,N,N9,N9-tetramethyl-6-carboxyrhodamine (TAM) ( Table S1 ). Cards were loaded by mixing 50 ml DNA extract with 50 ml TaqMan Environmental Mastermix 2.0 (Life Technologies). This reaction mix was then pipetted into the inlet port of each channel. For each run, seven channels were loaded with DNA extract and one channel with water (to serve as a negative control). Cards were centrifuged (twice for 1 min each at 1200 g) and sealed and the inlet ports were removed following the manufacturer's instructions. Cards were run on a ViiA 7 real-time PCR system (Life Technologies) using PCR cycling conditions of 60 uC for 30 s and 95 uC for 10 min, followed by 40 cycles of 95 uC for 15 s and 60 uC for 1 min. Real-time PCR results were reported in terms of C q , the cycle number within which fluorescence first exceeded 0.2 U in each PCR.
FilmArray PCR. The FilmArray (Idaho Technologies) PCR consumable is a single-use disposable pouch containing freeze-dried reagents. Biothreat v2.2 pouches were used in this study, which contain 28 PCR assays for 17 different potential biological threat agents (including bacteria, DNA and RNA viruses and agents associated with toxin production) and four PCRs assays that act as PCR and DNA/RNA extraction controls. Microfluidic chambers for cell lysis, magnetic bead-based DNA extraction and purification and a two-step nested PCR approach (fresh PCR reagents at each step) are incorporated into each pouch. Biothreat v2.2 pouches contain three PCR assays to B. anthracis (to chromosomal, pXO1 and pXO2 targets), two PCR assays to F. tularensis (to two chromosomal targets) and two PCR assays to Y. pestis (to pPCP and pMT targets). All PCR assays on the pouch have been designed and validated by the manufacturer and assay sequence information is not provided. In our hands, all FilmArray PCRs reported in this study were shown to be specific for their target Multiplex PCR screening of murine model samples agents/genes. These studies included specificity trials with DNA from 10 B. anthracis strains, 15 other Bacillus spp., seven F. tularensis strains, eight Y. pestis strains and 25 other Yersinia spp. (data not shown).
All FilmArray PCR analysis was carried out under BSL3 safety conditions. Whole-blood samples were processed from the same mice from which DNA had been extracted previously by adding 250 ml aliquots to a tube containing 500 ml FilmArray Sample Buffer, which also contained 20 mg proteinase K (Qiagen). In four cases, 250 ml blood was not available and 100 ml aliquots were processed instead; from a number of other mice, additional blood was not available for FilmArray analysis. Samples were incubated for 5 min at room temperature and then added to a pouch using a syringe following the manufacturer's instructions. Of the total 750 ml sample volume, 300 ml was delivered into the pouch, implying that~100 ml of sample was processed and analysed. Pouches were run on the FilmArray PCR platform using FilmArray Instrument Control software (Idaho Technologies) and the Blood v1.0 protocol. After addition of the sample to the pouch and insertion of the pouch into the platform, no further operative intervention was required. Realtime PCR results were recorded, as reported by the system, as a simple end-point 'yes' or 'no' result. Real-time PCR data were checked using FilmArray PCR evaluation software (Idaho Technologies) to confirm that amplification plot and melting curves had been produced as expected. Although it is possible to obtain C q -type data after a FilmArray PCR, we did not record the values in this study, as the nested PCR approach meant that there was significant variation in the values obtained, which were not comparable to the C q values produced by the singleplex and Array Card PCR assays.
RESULTS

Bacterial culture
The plate counts of bacterial load following microbiological culture of all samples tested in this study are summarized in Tables 
Singleplex PCR
The PCR results from each murine model are summarized in Tables 1-3 . Twenty DNA extracts needed to be diluted in water (1 : 10) to mitigate the effect of residual PCR inhibitors. This was determined from the results of a DNA extraction control assay performed on each extract (data not shown). At least one singleplex PCR-positive result was returned from all blood samples (all agents) with estimated bacterial loads of 10 3 c.f.u. ml 21 or higher, as determined by blood culture. Samples with estimated bacterial loads below 10 3 c.f.u. ml 21 returned both positive and negative singleplex PCR results. Five samples from the Y. pestis model (48 h, mice 3 and 5; 72 h, mice 3, 4 and 8) returned singleplex PCR-positive results from samples where no viable bacterial cells were detected by blood culture.
Array Card PCR results
On the Array Card architecture, the pXO1-MGB PCR returned a positive result from two of 13 B. anthracis model samples tested. These samples had estimated bacterial loads in the range of 10 3 and 10 4 c.f.u. ml
21
. As expected, the B. anthracis pXO2 Array Card PCR did not return any positive results as the strain used in the model (STI) did not harbour the pXO2 plasmid. The F. tularensis FTT0376 Array Card PCR returned at least one positive PCR result from two of 29 F. tularensis model samples tested (with estimated bacterial loads in the range of 10 2 and 10 3 c.f.u. ml 21 ). No positive results were returned from the Array Card FTT0523 PCR, even though this assay is known to detect the infecting Schu4 strain. Y. pestis Array Card PCRs (mpbA-MGB, pMT-MGB and pPCP-MGB PCRs) returned at least one PCR-positive result (from one of the three assays) from 10 of 24 samples tested. All three samples with estimated bacterial loads in the range of 10 6 c.f.u. ml 21 returned a PCR-positive result. All samples with estimated bacterial loads of 10 3 c.f.u. ml 21 or more returned a PCR-positive result. Below this range, no PCR-positive results were returned. An unexpected pXO2-MGB PCR-positive result was returned from the Y. pestisinfected mouse 6 DNA extract at 72 h. The presence of contaminating B. anthracis DNA in this extract was indicated by singleplex PCR. This was assumed to have been introduced inadvertently to the extract after transfer to a BSL2 laboratory, as a pXO2-negative B. anthracis strain (STI) was used in the murine model.
FilmArray PCR results
At least one FilmArray PCR result was generated from all samples estimated by bacterial culture to contain bacterial loads of 10 3 c.f.u. 
Comparison of capabilities and statistical analysis
The results generated from bacterial culture and each PCR capability are summarized in Table 4 in a binary format, with a positive result being defined as either (i) at least one bacterial colony being observed after culture of neat blood aliquots or (ii) at least one PCR-positive replicate, from any capability, per sample. Using this definition, the *Results are shown as the C q value, which indicates the PCR cycle number at which fluorescence was first detected, or as +, indicating a positive PCR result, or 2, indicating a negative PCR result. DDNA extract was diluted 1 : 10 to reduce the level of PCR inhibitors. dFilmArray analysis was conducted on a starting blood volume of 100 ml rather than the standard 250 ml.
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Journal of Medical Microbiology 61 Table 5 . Briefly, in the B. anthracis model, there was no significant difference between the detection rate of blood culture and FilmArray PCR. Both these methods were shown to have a significantly higher positive rate than the singleplex or Array Card PCR. In the F. tularensis model, blood culture gave significantly higher positive rates than the three PCR capabilities. Within the PCR capabilities, singleplex and FilmArray PCRs gave a significantly higher PCR-positive rate than the Array Card PCR. In the Y. pestis model, there was no significant difference in results among any of the technologies. It was not possible to conduct statistical analysis of the performance of each technology across all models as there was such a difference between the results across each agent. If all results were included in one model, most of the variation in the model would be due to the differences between the agents and any significant differences between the methods would probably be dependent on the differences between the agents.
DISCUSSION
The results presented in this study indicate that a multiplexed PCR approach could be used as a tool for rapid identification of the causal agent of a variety of acute infectious diseases. This would still require a clinician to order the tests at admission and an appropriate PCR platform and consumables being readily available in a hospital setting but the burden on the clinician in having to decide which specific tests to conduct would be reduced. For both the Array Card and the FilmArray platforms, cards and pouches for respiratory agents, which cause a large number of generic flu and fever-type diseases, have also been developed (Caliendo, 2011; Kodani et al., 2011) . This could help rule in or out a large number of diseases that cause initial symptoms similar to those found with acute disease.
In a recent case of inhalational anthrax (Anaraki et al., 2008) , a patient presented to hospital with a 2-day history of fever. A preliminary identification of B. anthracis from blood culture 3 days after admission resulted in a change of antibiotic therapy. Although this report did not disclose the blood titre of B. anthracis within the infected patient, a previous study (Rossi et al., 2008) examined the blood titres of nine African green monkeys infected via an inhalation route with B. anthracis. The first detected levels of bacteraemia in the eight monkeys that developed disease were ,10 3 c.f.u. ml 21 (two cases), 10 2 c.f.u. ml 21 (four cases) and 10 1 c.f.u. ml 21 (two cases). In some cases, the onset of bacteraemia was not immediately associated with observable disease symptoms. Although care must be taken when extrapolating results from a murine model to a primate model and then to human disease progression, the FilmArray PCR capability did detect all B. anthracis murine model blood samples with a titre of 10 3 c.f.u. ml 21 and above, four of five samples at the 10 2 c.f.u. ml 21 level and also individual samples at the 10 1 c.f.u. ml 21 level and below.
Of the two PCR screening capabilities evaluated in this study, the prototype Array Cards did not perform as well as the FilmArray PCR platform in the B. anthracis and F. *Defined as bacterial growth (at least one colony) observed after culture, or least one agent PCR assay per PCR capability returning a positive result out of the number of samples tested. The number in parentheses indicates the subset comprising the number of samples where the presence of target bacteria was identified by at least one of the capabilities, plate counts or PCR. DNumber of samples testing positive using the criteria defined above out of the samples tested within the subset of samples where the presence of agent had been indicated by at least one of the technologies.
S. A. Weller and others
tularensis models. As reported previously (Rachwal et al., 2012) , the Array Card architecture has been designed for gene-expression studies where cDNA at the nanogram level is analysed. Therefore, there has been no driver for the manufacturer to optimize the cards for detection of bacterial DNA at low levels (equivalent to the femtogram scale). This and other factors, such as the stochastic distribution of target DNA at low concentrations (Taberlet et al., 1996) , mean that the PCR assays on the card are generally 1 log less sensitive than the same PCRs in singleplex format, an observation found in other Array Card studies (Kodani et al., 2011) . The architecture of the cards implies that increasing the number of assays to a given agent within an Array Card channel increases the chances of detecting that agent. It was notable that, in the model within which the Array Card performed at the same level as all the other technologies (Y. pestis), six individual PCR chambers containing Y. pestis PCRs were present compared with two replicates for the B. anthracis samples (with the pXO2 PCR being redundant with the choice of the STI strain) and four PCR replicates for the F. tularensis model.
Another reason for the relatively poor performance of the cards in B. anthracis and F. tularensis models may be attributable to the sample type (whole blood) and DNA extraction approach. We tested DNA extracts produced by a common spin column-based method for a project evaluating the performance of singleplex PCRs. The results of the singleplex study indicated the presence of residual PCR inhibitors within the sample set, with six extracts only producing a positive result after a 1 : 10 dilution of the extract. Of these six diluted extracts, only two gave a PCRpositive result with the Array Card PCRs. As might be expected, this indicated that the requirement to dilute a DNA extract to remove PCR inhibitors has more of a detrimental effect on the Array Card PCR sensitivity. We did use a PCR master mix (Life Technologies Environmental Mastermix 2.0) marketed as having tolerance to PCR inhibitors (including those found in clinical samples) in an attempt to mitigate against the presence of inhibitors and negate the need to test 1 : 10-diluted extracts. However, once the study was under way, a test of neat, inhibited DNA extracts with this master mix indicated that there was no tolerance to the inhibitors present in our DNA extracts.
The study of Kodani et al. (2011) used Array Cards to test 292 clinical samples for 21 respiratory pathogen targets, with all samples processed using a magnetic bead-based DNA extraction method. In this study, the Array Cards detected 89 % of samples that were detected by equivalent singleplex PCR assays. This compares to the results of our study for the detection rates (from samples shown to contain agent) of singleplex (60.4 %) against Array Card (33.3 %) PCRs, indicating that the Array Cards detected only 55.1 % of samples where a singleplex PCR-positive result was returned. Our study and that of Kodani et al. (2011) indicate that the whole assay process (sample collection, DNA extraction and DNA purification) must be fully optimized to the Array Card system to obtain the best results. A recent study (Regan et al., 2012) indicated that a magnetic bead-based DNA extraction system reduced the effects of PCR inhibitors from blood culture fluids when compared with the silica column method used in this study. Using this work as a template, in the future we will look to optimize the entire assay system to deliver concentrated and inhibitor-free DNA extracts to the Array Cards. Other changes to the method that could improve the Array Card sensitivity are discussed in greater detail in a previous publication (Rachwal et al., 2012) .
If all aspects of the Array Card assay system could be optimized, it could offer several favourable attributes. These include the ability to test eight samples in one run, user control over which assays are placed on the cards and also an increased flexibility in changing assays. The spatial separation of all Array Card PCRs would allow assays on the cards to be changed easily without reoptimization of a highly parallel multiplex PCR assay. This could aid the No evidence of PCR inhibition (from the inbuilt DNA extraction control assay) was observed when testing whole-blood samples and thus there was no requirement to dilute bloods 1 : 10 to facilitate detection. The magnetic bead-based DNA extraction system may be a factor. In addition, the multiple assay per agent format appears, at the low concentrations of agent, to increase the chances of agent detection. There were several incidences in our study where FilmArray detection was based on only one PCR (of two or three available target assays) returning a positive result. As discussed previously, DNA can be distributed stochastically within a sample and more assays to an agent present in a system can increase the chances of detecting that agent at low concentrations. Another factor in the performance of the FilmArray may simply be automation and subsequent ease of use, with few steps required to analyse samples and thus a reduced risk of operative error.
In this study, we used bacterial culture from blood, commonly regarded as the 'gold standard' approach in clinical microbiology, to benchmark the performance of each PCR capability. Bacterial culture was shown to be the best-performing detection method from the F. tularensis model, although its clinical utility was limited by the time taken for the culture to grow (3-5 days for F. tularensis) and then the time taken to identify the culture generated. Bacterial culture, notably from samples within the Y. pestis model, was also shown to be capable of reporting falsenegative results. This may be due to very low bacterial titres or the presence of non-viable cells within the samples, as PCR does not indicate cell viability. However, the FilmArray assay also detects genetic material from organisms that are impossible to culture in standard microbiological media (DNA and RNA viruses), and the Array Card PCR technology (with the use of an appropriate nucleic acid extraction procedure and PCR reagents) could also be developed to test for such agents. Thus, in areas such as time to result and overall coverage of agents, multiplex PCR offers clear advantages, which could either complement or replace a culture approach, especially as the number of agents that can be tested for on such platforms increases in the future.
In this study, we also only tested whole-blood samples for agent. Despite the advantages of both PCR and bacterial culture, each technology still requires a circulating agent for detection/identification to be facilitated. Some agents that cause acute disease, such as Burkholderia mallei (Ulrich et al., 2006) , do not result in high bacterial blood titres in infected individuals. Therefore, an appropriate, uniform, clinical sample type for all PCRs on a multiplexed platform consumable may not be available. This may require other sample types such as urine or sputum to be tested (Richardson et al., 2012) , although this would require a clinician to be aware of potential causes of false-negative results for all agents present. In the future, monitoring of the post-exposure host immune response may facilitate pre-symptomatic detection of infection in the absence of detectable levels of circulating agent (Lukaszewski et al., 2008) , although such an approach will still need an indication of exposure in order to begin testing.
